UTIs and Ozempic: Clinical Facts and Safety

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Urinary tract infections are not listed in official clinical trial data as a direct side effect of semaglutide (Ozempic). However, indirect mechanisms—including dehydration, reduced fluid intake, and glucose excretion in urine—may elevate UTI risk in some patients. Clinical vigilance and preventive measures remain important during GLP-1 therapy.

Understanding potential UTI risk during GLP-1 treatment matters because recognizing causative mechanisms allows patients and providers to implement targeted prevention strategies. PlexusDx supports precision-informed decision-making by considering individual baseline health markers and genetic predispositions that may influence infection susceptibility, enabling more personalized safety planning.

How GLP-1 Medications May Indirectly Affect Urinary Tract Health

Semaglutide itself is not a direct UTI-causing agent based on clinical trial data. However, GLP-1 agonists alter glucose metabolism and fluid balance. Reduced fluid intake due to appetite suppression, combined with higher urinary glucose concentration (glucosuria), may create an environment favorable to bacterial growth in the urinary tract.

Dehydration is a recognized risk factor for UTIs across all populations. Patients on GLP-1 therapy often report decreased thirst sensation and reduced oral intake. Maintaining adequate hydration—typically 2–3 liters daily unless contraindicated—is a practical preventive measure supported by general urological and endocrinology guidelines.

Clinical Evidence: What Trials and Real-World Data Show

Pivotal trials for semaglutide (SUSTAIN and SELECT series) did not identify UTI as a primary safety signal. However, postmarketing reports and patient cohort studies suggest occasional UTI clustering in GLP-1 users, likely attributable to secondary factors rather than direct pharmacological action. Causality remains unclear and requires provider-level assessment.

Data Source / Finding	Clinical Relevance
SUSTAIN trials (semaglutide)	UTI not listed as primary adverse event; baseline UTI rate consistent with general population
Dehydration and glucosuria mechanism	Both are established UTI risk factors; GLP-1 therapy may amplify these via appetite suppression and glycemic changes
Postmarketing reports (FDA)	Isolated UTI cases reported; no causal link established; frequencies lower than background rates
Prevention-focused outcomes	Adequate hydration and regular urinalysis reduce UTI incidence in at-risk GLP-1 users

Recognizing UTI Symptoms and When to Seek Care

Early UTI symptoms include dysuria (painful urination), urinary frequency, urgency, and suprapubic discomfort. Some patients experience cloudy or blood-tinged urine. Fever or flank pain may indicate upper urinary tract involvement (pyelonephritis) and requires prompt medical evaluation. Symptom recognition is key during GLP-1 therapy.

If UTI symptoms emerge after starting semaglutide or tirzepatide, contact your healthcare provider promptly for urinalysis and possible urine culture. Do not delay treatment; untreated UTIs can progress to pyelonephritis. Your provider can assess whether continuation, dose adjustment, or temporary pause of GLP-1 therapy is appropriate based on clinical context.

Practical Prevention Strategies and Provider Monitoring

Prevention centers on maintaining hydration, monitoring urinary symptoms, and avoiding behaviors that concentrate urine. Drink at least 2–3 liters of water daily unless your provider advises otherwise. Urinate regularly; avoid holding urine for prolonged periods. Some patients benefit from baseline and periodic urinalysis to detect asymptomatic bacteriuria, especially if recurrent UTIs occur.

Providers should assess baseline UTI history, diabetes status, and urological anatomy before starting GLP-1 therapy. Patients with prior recurrent UTIs, spinal cord injury, or neurogenic bladder may warrant closer monitoring or prophylactic measures. Individual risk stratification—informed by medical history and potentially genetic predisposition to infection—supports safer, more personalized treatment plans.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines genetic variants in GLP-1 and metabolic pathways (GLP1R rs6923761, FTO rs9939609) that may provide context for an individual's metabolic response to GLP-1 therapy. While genetic data does not directly predict UTI risk, it may help reveal predispositions in glucose regulation and fluid balance that could indirectly influence infection susceptibility. This information should be interpreted with a qualified healthcare provider.

The genetic test reveals predispositions in peptide metabolism and glucose handling—not exact medication response or UTI risk. Some individuals may experience greater fluctuations in blood glucose or fluid retention patterns during GLP-1 initiation based on their genetic profile. Understanding these predispositions can support a more informed baseline assessment and help guide personalized hydration and monitoring strategies.

By reviewing genetic predispositions alongside medical history and baseline urinary health markers, patients and providers can develop targeted prevention plans. This personalized approach—combining genetic context, clinical evidence, and individual risk factors—helps ensure that GLP-1 therapy proceeds safely with appropriate monitoring and lifestyle modifications tailored to each person's needs.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.